Diagnostic Reverse-Transcription Polymerase Chain Reaction Kit for Filoviruses Based on the Strain Collections of all European Biosafety Level 4 Laboratories
Identifieur interne : 000C10 ( Istex/Corpus ); précédent : 000C09; suivant : 000C11Diagnostic Reverse-Transcription Polymerase Chain Reaction Kit for Filoviruses Based on the Strain Collections of all European Biosafety Level 4 Laboratories
Auteurs : Marcus Panning ; Thomas Laue ; Stephan Ölschlager ; Markus Eickmann ; Stephan Becker ; Sabine Raith ; Marie-Claude Georges Courbot ; Mikael Nilsson ; Robin Gopal ; Ake Lundkvist ; Antonino Di Caro ; David Brown ; Hermann Meyer ; Graham Lloyd ; Beate M. Kümmerer ; Stephan Günther ; Christian DrostenSource :
- The Journal of Infectious Diseases [ 0022-1899 ] ; 2007.
Abstract
A network of European biosafety level 4 laboratories has designed the first industry-standard molecular assay for all filoviruses species, based on the strain collections of all participants. It uses 5 optimized L gene primers and 3 probes, as well as an internal control with a separate detection probe. Detection limits (probit analysis, 95% detection chance) were as follows: Zaire ebolavirus, 487 copies/mL of plasma; Sudan ebolavirus Maleo, 586 copies/mL; Sudan ebolavirus Gulu, 1128 copies/mL; Cote d'Ivoire ebolavirus, 537 copies/mL; Reston ebolavirus, 4546 copies/mL; Lake Victoria marburgvirus Musoke, 860 copies/mL; and Lake Victoria marburgvirus Ravn, 1551 copies/mL. The assay facilitates reliable detection or exclusion screening of filovirus infections.
Url:
DOI: 10.1086/520600
Links to Exploration step
ISTEX:132FFE9AD7A1A2EEDB40F77F78284659D4FF368ALe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Diagnostic Reverse-Transcription Polymerase Chain Reaction Kit for Filoviruses Based on the Strain Collections of all European Biosafety Level 4 Laboratories</title><author><name sortKey="Panning, Marcus" sort="Panning, Marcus" uniqKey="Panning M" first="Marcus" last="Panning">Marcus Panning</name><affiliation><mods:affiliation>Bernhard-Nocht Institute for Tropical Medicine, Hamburg</mods:affiliation></affiliation></author><author><name sortKey="Laue, Thomas" sort="Laue, Thomas" uniqKey="Laue T" first="Thomas" last="Laue">Thomas Laue</name><affiliation><mods:affiliation>Qiagen, Hamburg</mods:affiliation></affiliation></author><author><name sortKey="Olschlager, Stephan" sort="Olschlager, Stephan" uniqKey="Olschlager S" first="Stephan" last="Ölschlager">Stephan Ölschlager</name><affiliation><mods:affiliation>Bernhard-Nocht Institute for Tropical Medicine, Hamburg</mods:affiliation></affiliation></author><author><name sortKey="Eickmann, Markus" sort="Eickmann, Markus" uniqKey="Eickmann M" first="Markus" last="Eickmann">Markus Eickmann</name><affiliation><mods:affiliation>University of Marburg, Marburg, Germany</mods:affiliation></affiliation></author><author><name sortKey="Becker, Stephan" sort="Becker, Stephan" uniqKey="Becker S" first="Stephan" last="Becker">Stephan Becker</name><affiliation><mods:affiliation>University of Marburg, Marburg, Germany</mods:affiliation></affiliation></author><author><name sortKey="Raith, Sabine" sort="Raith, Sabine" uniqKey="Raith S" first="Sabine" last="Raith">Sabine Raith</name><affiliation><mods:affiliation>Qiagen, Hamburg</mods:affiliation></affiliation></author><author><name sortKey="Courbot, Marie Claude Georges" sort="Courbot, Marie Claude Georges" uniqKey="Courbot M" first="Marie-Claude Georges" last="Courbot">Marie-Claude Georges Courbot</name><affiliation><mods:affiliation>Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France</mods:affiliation></affiliation></author><author><name sortKey="Nilsson, Mikael" sort="Nilsson, Mikael" uniqKey="Nilsson M" first="Mikael" last="Nilsson">Mikael Nilsson</name><affiliation><mods:affiliation>Swedish Centre for Infectious Disease Control, Solna, Sweden</mods:affiliation></affiliation></author><author><name sortKey="Gopal, Robin" sort="Gopal, Robin" uniqKey="Gopal R" first="Robin" last="Gopal">Robin Gopal</name><affiliation><mods:affiliation>Health Protection Agency, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Lundkvist, Ake" sort="Lundkvist, Ake" uniqKey="Lundkvist A" first="Ake" last="Lundkvist">Ake Lundkvist</name><affiliation><mods:affiliation>Swedish Centre for Infectious Disease Control, Solna, Sweden</mods:affiliation></affiliation></author><author><name sortKey="Di Caro, Antonino" sort="Di Caro, Antonino" uniqKey="Di Caro A" first="Antonino" last="Di Caro">Antonino Di Caro</name><affiliation><mods:affiliation>National Institute for Infectious Diseases “L. Spallanzani”, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Brown, David" sort="Brown, David" uniqKey="Brown D" first="David" last="Brown">David Brown</name><affiliation><mods:affiliation>Health Protection Agency, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Meyer, Hermann" sort="Meyer, Hermann" uniqKey="Meyer H" first="Hermann" last="Meyer">Hermann Meyer</name><affiliation><mods:affiliation>Bundeswehr Institute of Microbiology, Munich, Germany</mods:affiliation></affiliation></author><author><name sortKey="Lloyd, Graham" sort="Lloyd, Graham" uniqKey="Lloyd G" first="Graham" last="Lloyd">Graham Lloyd</name><affiliation><mods:affiliation>Health Protection Agency Porton Down, Salisbury, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Kummerer, Beate M" sort="Kummerer, Beate M" uniqKey="Kummerer B" first="Beate M." last="Kümmerer">Beate M. Kümmerer</name><affiliation><mods:affiliation>Bernhard-Nocht Institute for Tropical Medicine, Hamburg</mods:affiliation></affiliation></author><author><name sortKey="Gunther, Stephan" sort="Gunther, Stephan" uniqKey="Gunther S" first="Stephan" last="Günther">Stephan Günther</name><affiliation><mods:affiliation>Bernhard-Nocht Institute for Tropical Medicine, Hamburg</mods:affiliation></affiliation></author><author><name sortKey="Drosten, Christian" sort="Drosten, Christian" uniqKey="Drosten C" first="Christian" last="Drosten">Christian Drosten</name><affiliation><mods:affiliation>Bernhard-Nocht Institute for Tropical Medicine, Hamburg</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: drosten@bni-hamburg.de</mods:affiliation></affiliation><affiliation><mods:affiliation>Reprints or correspondence: Dr. Christian Drosten, Bernhard Nocht Institute for Tropical Medicine, Clinical Virology, Bernhard-Nocht Str. 74, 20359 Hamburg, Germany (drosten@bni-hamburg.de).</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:132FFE9AD7A1A2EEDB40F77F78284659D4FF368A</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1086/520600</idno><idno type="url">https://api.istex.fr/ark:/67375/HXZ-GF4DFKKG-B/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000C10</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000C10</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Diagnostic Reverse-Transcription Polymerase Chain Reaction Kit for Filoviruses Based on the Strain Collections of all European Biosafety Level 4 Laboratories</title><author><name sortKey="Panning, Marcus" sort="Panning, Marcus" uniqKey="Panning M" first="Marcus" last="Panning">Marcus Panning</name><affiliation><mods:affiliation>Bernhard-Nocht Institute for Tropical Medicine, Hamburg</mods:affiliation></affiliation></author><author><name sortKey="Laue, Thomas" sort="Laue, Thomas" uniqKey="Laue T" first="Thomas" last="Laue">Thomas Laue</name><affiliation><mods:affiliation>Qiagen, Hamburg</mods:affiliation></affiliation></author><author><name sortKey="Olschlager, Stephan" sort="Olschlager, Stephan" uniqKey="Olschlager S" first="Stephan" last="Ölschlager">Stephan Ölschlager</name><affiliation><mods:affiliation>Bernhard-Nocht Institute for Tropical Medicine, Hamburg</mods:affiliation></affiliation></author><author><name sortKey="Eickmann, Markus" sort="Eickmann, Markus" uniqKey="Eickmann M" first="Markus" last="Eickmann">Markus Eickmann</name><affiliation><mods:affiliation>University of Marburg, Marburg, Germany</mods:affiliation></affiliation></author><author><name sortKey="Becker, Stephan" sort="Becker, Stephan" uniqKey="Becker S" first="Stephan" last="Becker">Stephan Becker</name><affiliation><mods:affiliation>University of Marburg, Marburg, Germany</mods:affiliation></affiliation></author><author><name sortKey="Raith, Sabine" sort="Raith, Sabine" uniqKey="Raith S" first="Sabine" last="Raith">Sabine Raith</name><affiliation><mods:affiliation>Qiagen, Hamburg</mods:affiliation></affiliation></author><author><name sortKey="Courbot, Marie Claude Georges" sort="Courbot, Marie Claude Georges" uniqKey="Courbot M" first="Marie-Claude Georges" last="Courbot">Marie-Claude Georges Courbot</name><affiliation><mods:affiliation>Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France</mods:affiliation></affiliation></author><author><name sortKey="Nilsson, Mikael" sort="Nilsson, Mikael" uniqKey="Nilsson M" first="Mikael" last="Nilsson">Mikael Nilsson</name><affiliation><mods:affiliation>Swedish Centre for Infectious Disease Control, Solna, Sweden</mods:affiliation></affiliation></author><author><name sortKey="Gopal, Robin" sort="Gopal, Robin" uniqKey="Gopal R" first="Robin" last="Gopal">Robin Gopal</name><affiliation><mods:affiliation>Health Protection Agency, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Lundkvist, Ake" sort="Lundkvist, Ake" uniqKey="Lundkvist A" first="Ake" last="Lundkvist">Ake Lundkvist</name><affiliation><mods:affiliation>Swedish Centre for Infectious Disease Control, Solna, Sweden</mods:affiliation></affiliation></author><author><name sortKey="Di Caro, Antonino" sort="Di Caro, Antonino" uniqKey="Di Caro A" first="Antonino" last="Di Caro">Antonino Di Caro</name><affiliation><mods:affiliation>National Institute for Infectious Diseases “L. Spallanzani”, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Brown, David" sort="Brown, David" uniqKey="Brown D" first="David" last="Brown">David Brown</name><affiliation><mods:affiliation>Health Protection Agency, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Meyer, Hermann" sort="Meyer, Hermann" uniqKey="Meyer H" first="Hermann" last="Meyer">Hermann Meyer</name><affiliation><mods:affiliation>Bundeswehr Institute of Microbiology, Munich, Germany</mods:affiliation></affiliation></author><author><name sortKey="Lloyd, Graham" sort="Lloyd, Graham" uniqKey="Lloyd G" first="Graham" last="Lloyd">Graham Lloyd</name><affiliation><mods:affiliation>Health Protection Agency Porton Down, Salisbury, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Kummerer, Beate M" sort="Kummerer, Beate M" uniqKey="Kummerer B" first="Beate M." last="Kümmerer">Beate M. Kümmerer</name><affiliation><mods:affiliation>Bernhard-Nocht Institute for Tropical Medicine, Hamburg</mods:affiliation></affiliation></author><author><name sortKey="Gunther, Stephan" sort="Gunther, Stephan" uniqKey="Gunther S" first="Stephan" last="Günther">Stephan Günther</name><affiliation><mods:affiliation>Bernhard-Nocht Institute for Tropical Medicine, Hamburg</mods:affiliation></affiliation></author><author><name sortKey="Drosten, Christian" sort="Drosten, Christian" uniqKey="Drosten C" first="Christian" last="Drosten">Christian Drosten</name><affiliation><mods:affiliation>Bernhard-Nocht Institute for Tropical Medicine, Hamburg</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: drosten@bni-hamburg.de</mods:affiliation></affiliation><affiliation><mods:affiliation>Reprints or correspondence: Dr. Christian Drosten, Bernhard Nocht Institute for Tropical Medicine, Clinical Virology, Bernhard-Nocht Str. 74, 20359 Hamburg, Germany (drosten@bni-hamburg.de).</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">The Journal of Infectious Diseases</title><title level="j" type="abbrev">The Journal of Infectious Diseases</title><idno type="ISSN">0022-1899</idno><idno type="eISSN">1537-6613</idno><imprint><publisher>The University of Chicago Press</publisher><date type="published">2007</date><biblScope unit="vol">196</biblScope><biblScope unit="issue">Supplemet_2</biblScope><biblScope unit="page" from="S199">S199</biblScope><biblScope unit="page" to="S204">S204</biblScope></imprint><idno type="ISSN">0022-1899</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0022-1899</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract">A network of European biosafety level 4 laboratories has designed the first industry-standard molecular assay for all filoviruses species, based on the strain collections of all participants. It uses 5 optimized L gene primers and 3 probes, as well as an internal control with a separate detection probe. Detection limits (probit analysis, 95% detection chance) were as follows: Zaire ebolavirus, 487 copies/mL of plasma; Sudan ebolavirus Maleo, 586 copies/mL; Sudan ebolavirus Gulu, 1128 copies/mL; Cote d'Ivoire ebolavirus, 537 copies/mL; Reston ebolavirus, 4546 copies/mL; Lake Victoria marburgvirus Musoke, 860 copies/mL; and Lake Victoria marburgvirus Ravn, 1551 copies/mL. The assay facilitates reliable detection or exclusion screening of filovirus infections.</div></front></TEI><istex><corpusName>oup</corpusName><keywords><teeft><json:string>primer</json:string><json:string>zebov</json:string><json:string>ebolavirus</json:string><json:string>assay</json:string><json:string>loviruses</json:string><json:string>lovirus</json:string><json:string>sebov</json:string><json:string>hemorrhagic</json:string><json:string>ciebov</json:string><json:string>drosten</json:string><json:string>marburg</json:string><json:string>gure</json:string><json:string>gabon</json:string><json:string>rebov</json:string><json:string>ebola</json:string><json:string>probit analysis</json:string><json:string>internal control</json:string><json:string>point value</json:string><json:string>clin microbiol</json:string><json:string>competitive internal control</json:string><json:string>zebov gabon</json:string><json:string>cote ebolavirus</json:string><json:string>reston ebolavirus</json:string><json:string>infectious disease</json:string><json:string>target region</json:string><json:string>lovirus infection</json:string><json:string>strain collection</json:string><json:string>lassa virus</json:string><json:string>yellow fever virus</json:string><json:string>european biosafety level</json:string><json:string>genbank accession</json:string><json:string>sebov gulu</json:string><json:string>oligonucleotide binding site</json:string><json:string>outbreak</json:string><json:string>marv</json:string><json:string>molecular assay</json:string><json:string>virus strain</json:string><json:string>binding site</json:string><json:string>test kit</json:string><json:string>single reaction</json:string><json:string>sudan ebolavirus</json:string><json:string>marv ravn</json:string><json:string>bottom panel</json:string><json:string>rapid detection</json:string><json:string>zaire ebolavirus</json:string><json:string>target gene</json:string><json:string>polymerase chain reaction</json:string><json:string>positive result</json:string><json:string>assay design</json:string><json:string>detection probe</json:string><json:string>marv musoke</json:string><json:string>dengue virus</json:string><json:string>west nile virus</json:string><json:string>present study</json:string><json:string>lovirus strain</json:string><json:string>tropical medicine</json:string><json:string>ebola virus</json:string><json:string>hemorrhagic fever virus</json:string><json:string>virus</json:string></teeft></keywords><author><json:item><name>Marcus Panning</name><affiliations><json:string>Bernhard-Nocht Institute for Tropical Medicine, Hamburg</json:string></affiliations></json:item><json:item><name>Thomas Laue</name><affiliations><json:string>Qiagen, Hamburg</json:string></affiliations></json:item><json:item><name>Stephan Ölschlager</name><affiliations><json:string>Bernhard-Nocht Institute for Tropical Medicine, Hamburg</json:string></affiliations></json:item><json:item><name>Markus Eickmann</name><affiliations><json:string>University of Marburg, Marburg, Germany</json:string></affiliations></json:item><json:item><name>Stephan Becker</name><affiliations><json:string>University of Marburg, Marburg, Germany</json:string></affiliations></json:item><json:item><name>Sabine Raith</name><affiliations><json:string>Qiagen, Hamburg</json:string></affiliations></json:item><json:item><name>Marie-Claude Georges Courbot</name><affiliations><json:string>Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France</json:string></affiliations></json:item><json:item><name>Mikael Nilsson</name><affiliations><json:string>Swedish Centre for Infectious Disease Control, Solna, Sweden</json:string></affiliations></json:item><json:item><name>Robin Gopal</name><affiliations><json:string>Health Protection Agency, London, United Kingdom</json:string></affiliations></json:item><json:item><name>Ake Lundkvist</name><affiliations><json:string>Swedish Centre for Infectious Disease Control, Solna, Sweden</json:string></affiliations></json:item><json:item><name>Antonino di Caro</name><affiliations><json:string>National Institute for Infectious Diseases “L. Spallanzani”, Rome, Italy</json:string></affiliations></json:item><json:item><name>David Brown</name><affiliations><json:string>Health Protection Agency, London, United Kingdom</json:string></affiliations></json:item><json:item><name>Hermann Meyer</name><affiliations><json:string>Bundeswehr Institute of Microbiology, Munich, Germany</json:string></affiliations></json:item><json:item><name>Graham Lloyd</name><affiliations><json:string>Health Protection Agency Porton Down, Salisbury, United Kingdom</json:string></affiliations></json:item><json:item><name>Beate M. Kümmerer</name><affiliations><json:string>Bernhard-Nocht Institute for Tropical Medicine, Hamburg</json:string></affiliations></json:item><json:item><name>Stephan Günther</name><affiliations><json:string>Bernhard-Nocht Institute for Tropical Medicine, Hamburg</json:string></affiliations></json:item><json:item><name>Christian Drosten</name><affiliations><json:string>Bernhard-Nocht Institute for Tropical Medicine, Hamburg</json:string><json:string>E-mail: drosten@bni-hamburg.de</json:string><json:string>Reprints or correspondence: Dr. Christian Drosten, Bernhard Nocht Institute for Tropical Medicine, Clinical Virology, Bernhard-Nocht Str. 74, 20359 Hamburg, Germany (drosten@bni-hamburg.de).</json:string></affiliations></json:item></author><arkIstex>ark:/67375/HXZ-GF4DFKKG-B</arkIstex><language><json:string>unknown</json:string></language><originalGenre><json:string>research-article</json:string></originalGenre><abstract>A network of European biosafety level 4 laboratories has designed the first industry-standard molecular assay for all filoviruses species, based on the strain collections of all participants. It uses 5 optimized L gene primers and 3 probes, as well as an internal control with a separate detection probe. Detection limits (probit analysis, 95% detection chance) were as follows: Zaire ebolavirus, 487 copies/mL of plasma; Sudan ebolavirus Maleo, 586 copies/mL; Sudan ebolavirus Gulu, 1128 copies/mL; Cote d'Ivoire ebolavirus, 537 copies/mL; Reston ebolavirus, 4546 copies/mL; Lake Victoria marburgvirus Musoke, 860 copies/mL; and Lake Victoria marburgvirus Ravn, 1551 copies/mL. The assay facilitates reliable detection or exclusion screening of filovirus infections.</abstract><qualityIndicators><score>4.383</score><pdfWordCount>3099</pdfWordCount><pdfCharCount>20099</pdfCharCount><pdfVersion>1.2</pdfVersion><pdfPageCount>6</pdfPageCount><pdfPageSize>612 x 792 pts (letter)</pdfPageSize><pdfWordsPerPage>517</pdfWordsPerPage><pdfText>true</pdfText><refBibsNative>true</refBibsNative><abstractWordCount>107</abstractWordCount><abstractCharCount>767</abstractCharCount><keywordCount>0</keywordCount></qualityIndicators><title>Diagnostic Reverse-Transcription Polymerase Chain Reaction Kit for Filoviruses Based on the Strain Collections of all European Biosafety Level 4 Laboratories</title><pmid><json:string>17940950</json:string></pmid><genre><json:string>research-article</json:string></genre><host><title>The Journal of Infectious Diseases</title><language><json:string>unknown</json:string></language><issn><json:string>0022-1899</json:string></issn><eissn><json:string>1537-6613</json:string></eissn><publisherId><json:string>jid</json:string></publisherId><volume>196</volume><issue>Supplement-2</issue><pages><first>S199</first><last>S204</last></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date><json:string>2005</json:string><json:string>2007</json:string><json:string>2003</json:string></date><geogName><json:string>Lake Victoria</json:string><json:string>Barmah</json:string></geogName><orgName><json:string>Tib-Molbiol</json:string><json:string>European Commission</json:string><json:string>National Institute for Infectious Diseases</json:string><json:string>Health Protection Agency, London</json:string><json:string>Canada, the National Institutes of Health, the Canadian Institutes of Health Research, Cangene, CUH</json:string><json:string>Public Health Agency</json:string><json:string>Bernhard Nocht Institute for Tropical Medicine, Clinical Virology, Bernhard-Nocht Str</json:string><json:string>University of Marburg</json:string><json:string>Health Protection Agency</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>Marie-Claude Georges</json:string><json:string>Smith Carter</json:string><json:string>M. Kummerer</json:string><json:string>L. Spallanzani</json:string><json:string>Stephan Becker</json:string><json:string>Stephan Gunther</json:string><json:string>Graham Lloyd</json:string><json:string>Robin Gopal</json:string><json:string>Mikael Nilsson</json:string><json:string>Stephan Olschlager</json:string><json:string>Carola Busch</json:string><json:string>The</json:string><json:string>Sabine Raith</json:string><json:string>Hermann Meyer</json:string><json:string>David Brown</json:string><json:string>Markus Eickmann</json:string><json:string>Christian Drosten</json:string><json:string>Antonino di Caro</json:string><json:string>Stuart T. Nichol</json:string></persName><placeName><json:string>Nile</json:string><json:string>Berlin</json:string><json:string>Marburg</json:string><json:string>Germany</json:string><json:string>Uganda</json:string><json:string>Munich</json:string><json:string>Hamburg</json:string><json:string>Europe</json:string><json:string>America</json:string><json:string>Angola</json:string><json:string>Rome</json:string><json:string>Sudan</json:string><json:string>United Kingdom</json:string><json:string>Stockholm</json:string><json:string>France</json:string><json:string>European Union</json:string><json:string>Italy</json:string><json:string>Gabon</json:string><json:string>Sweden</json:string><json:string>Zaire</json:string><json:string>Salisbury</json:string><json:string>Lyon</json:string></placeName><ref_url><json:string>http://www.bni-hamburg.de/ebovalign</json:string></ref_url><ref_bibl><json:string>Panning et al.</json:string><json:string>[4]</json:string><json:string>[11]</json:string><json:string>[5, 12]</json:string><json:string>[1]</json:string><json:string>[10]</json:string><json:string>[3]</json:string><json:string>October 2006</json:string><json:string>[2]</json:string><json:string>[1, 5]</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/HXZ-GF4DFKKG-B</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - microbiology</json:string><json:string>2 - infectious diseases</json:string><json:string>2 - immunology</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - biomedical research</json:string><json:string>3 - microbiology</json:string></scienceMetrix><scopus><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Infectious Diseases</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Immunology and Allergy</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences biologiques fondamentales et appliquees. psychologie</json:string></inist></categories><publicationDate>2007</publicationDate><copyrightDate>2007</copyrightDate><doi><json:string>10.1086/520600</json:string></doi><id>132FFE9AD7A1A2EEDB40F77F78284659D4FF368A</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/HXZ-GF4DFKKG-B/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/HXZ-GF4DFKKG-B/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/HXZ-GF4DFKKG-B/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">Diagnostic Reverse-Transcription Polymerase Chain Reaction Kit for Filoviruses Based on the Strain Collections of all European Biosafety Level 4 Laboratories</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>The University of Chicago Press</publisher><availability><licence>© 2007 by the Infectious Diseases Society of America</licence></availability><date type="Copyright" when="2007">2007</date><date type="published">2007</date></publicationStmt><notesStmt><note type="content-type" source="research-article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</note><note type="publication-type" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="article"><analytic><title level="a" type="main">Diagnostic Reverse-Transcription Polymerase Chain Reaction Kit for Filoviruses Based on the Strain Collections of all European Biosafety Level 4 Laboratories</title><author xml:id="author-0000"><persName><surname>Panning</surname><forename type="first">Marcus</forename></persName><affiliation><orgName type="institution">Bernhard-Nocht Institute for Tropical Medicine</orgName><address><addrLine>Hamburg</addrLine></address></affiliation></author><author xml:id="author-0001"><persName><surname>Laue</surname><forename type="first">Thomas</forename></persName><affiliation><orgName type="institution">Qiagen</orgName><address><addrLine>Hamburg</addrLine></address></affiliation></author><author xml:id="author-0002"><persName><surname>Ölschlager</surname><forename type="first">Stephan</forename></persName><affiliation><orgName type="institution">Bernhard-Nocht Institute for Tropical Medicine</orgName><address><addrLine>Hamburg</addrLine></address></affiliation></author><author xml:id="author-0003"><persName><surname>Eickmann</surname><forename type="first">Markus</forename></persName><affiliation><orgName type="institution">University of Marburg</orgName><address><addrLine>Marburg, Germany</addrLine></address></affiliation></author><author xml:id="author-0004"><persName><surname>Becker</surname><forename type="first">Stephan</forename></persName><affiliation><orgName type="institution">University of Marburg</orgName><address><addrLine>Marburg, Germany</addrLine></address></affiliation></author><author xml:id="author-0005"><persName><surname>Raith</surname><forename type="first">Sabine</forename></persName><affiliation><orgName type="institution">Qiagen</orgName><address><addrLine>Hamburg</addrLine></address></affiliation></author><author xml:id="author-0006"><persName><surname>Courbot</surname><forename type="first">Marie-Claude Georges</forename></persName><affiliation><orgName type="institution">Unité de Biologie des Infections Virales Emergentes, Institut Pasteur</orgName><address><addrLine>Lyon, France</addrLine></address></affiliation></author><author xml:id="author-0007"><persName><surname>Nilsson</surname><forename type="first">Mikael</forename></persName><affiliation><orgName type="institution">Swedish Centre for Infectious Disease Control</orgName><address><addrLine>Solna, Sweden</addrLine></address></affiliation></author><author xml:id="author-0008"><persName><surname>Gopal</surname><forename type="first">Robin</forename></persName><affiliation><orgName type="institution">Health Protection Agency</orgName><address><addrLine>London, United Kingdom</addrLine></address></affiliation></author><author xml:id="author-0009"><persName><surname>Lundkvist</surname><forename type="first">Ake</forename></persName><affiliation><orgName type="institution">Swedish Centre for Infectious Disease Control</orgName><address><addrLine>Solna, Sweden</addrLine></address></affiliation></author><author xml:id="author-0010"><persName><surname>di Caro</surname><forename type="first">Antonino</forename></persName><affiliation><orgName type="institution">National Institute for Infectious Diseases “L. Spallanzani”</orgName><address><addrLine>Rome, Italy</addrLine></address></affiliation></author><author xml:id="author-0011"><persName><surname>Brown</surname><forename type="first">David</forename></persName><affiliation><orgName type="institution">Health Protection Agency</orgName><address><addrLine>London, United Kingdom</addrLine></address></affiliation></author><author xml:id="author-0012"><persName><surname>Meyer</surname><forename type="first">Hermann</forename></persName><affiliation><orgName type="institution">Bundeswehr Institute of Microbiology</orgName><address><addrLine>Munich, Germany</addrLine></address></affiliation></author><author xml:id="author-0013"><persName><surname>Lloyd</surname><forename type="first">Graham</forename></persName><affiliation><orgName type="institution">Health Protection Agency Porton Down, Salisbury</orgName><address><addrLine>United Kingdom</addrLine></address></affiliation></author><author xml:id="author-0014"><persName><surname>Kümmerer</surname><forename type="first">Beate M.</forename></persName><affiliation><orgName type="institution">Bernhard-Nocht Institute for Tropical Medicine</orgName><address><addrLine>Hamburg</addrLine></address></affiliation></author><author xml:id="author-0015"><persName><surname>Günther</surname><forename type="first">Stephan</forename></persName><affiliation><orgName type="institution">Bernhard-Nocht Institute for Tropical Medicine</orgName><address><addrLine>Hamburg</addrLine></address></affiliation></author><author xml:id="author-0016" role="corresp"><persName><surname>Drosten</surname><forename type="first">Christian</forename></persName><affiliation><orgName type="institution">Bernhard-Nocht Institute for Tropical Medicine</orgName><address><addrLine>Hamburg</addrLine></address></affiliation></author><idno type="istex">132FFE9AD7A1A2EEDB40F77F78284659D4FF368A</idno><idno type="ark">ark:/67375/HXZ-GF4DFKKG-B</idno><idno type="DOI">10.1086/520600</idno></analytic><monogr><title level="j" type="main">The Journal of Infectious Diseases</title><title level="j" type="abbrev">The Journal of Infectious Diseases</title><idno type="hwp">jinfdis</idno><idno type="publisher-id">jid</idno><idno type="pISSN">0022-1899</idno><idno type="eISSN">1537-6613</idno><imprint><publisher>The University of Chicago Press</publisher><date type="published">2007</date><biblScope unit="vol">196</biblScope><biblScope unit="issue">Supplemet_2</biblScope><biblScope unit="page" from="S199">S199</biblScope><biblScope unit="page" to="S204">S204</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><encodingDesc><schemaRef type="ODD" url="https://xml-schema.delivery.istex.fr/tei-istex.odd"></schemaRef><appInfo><application ident="pub2tei" version="1.0.41" when="2020-04-06"><label>pub2TEI-ISTEX</label><desc>A set of style sheets for converting XML documents encoded in various scientific publisher formats into a common TEI format.
<ref target="http://www.tei-c.org/">We use TEI</ref></desc></application></appInfo></encodingDesc><profileDesc><abstract><p>A network of European biosafety level 4 laboratories has designed the first industry-standard molecular assay for all filoviruses species, based on the strain collections of all participants. It uses 5 optimized L gene primers and 3 probes, as well as an internal control with a separate detection probe. Detection limits (probit analysis, 95% detection chance) were as follows: <hi rend="italic">Zaire ebolavirus</hi>, 487 copies/mL of plasma; <hi rend="italic">Sudan ebolavirus</hi> Maleo, 586 copies/mL; <hi rend="italic">Sudan ebolavirus</hi> Gulu, 1128 copies/mL; Cote <hi rend="italic">d'Ivoire ebolavirus</hi>, 537 copies/mL; <hi rend="italic">Reston ebolavirus</hi>, 4546 copies/mL; <hi rend="italic">Lake Victoria marburgvirus</hi> Musoke, 860 copies/mL; and <hi rend="italic">Lake Victoria marburgvirus</hi> Ravn, 1551 copies/mL. The assay facilitates reliable detection or exclusion screening of filovirus infections.</p></abstract><textClass ana="subject"><keywords scheme="heading"><term>Diagnostics</term></keywords></textClass><langUsage><language ident="EN"></language></langUsage></profileDesc><revisionDesc><change when="2020-04-06" who="#istex" xml:id="pub2tei">formatting</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/HXZ-GF4DFKKG-B/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="corpus oup, element #text not found" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0"</istex:xmlDeclaration><istex:docType PUBLIC="-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" URI="journalpublishing.dtd" name="istex:docType"></istex:docType><istex:document><article article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="hwp">jinfdis</journal-id>
<journal-id journal-id-type="publisher-id">jid</journal-id>
<journal-title>The Journal of Infectious Diseases</journal-title>
<abbrev-journal-title>The Journal of Infectious Diseases</abbrev-journal-title>
<issn pub-type="ppub">0022-1899</issn>
<issn pub-type="epub">1537-6613</issn>
<publisher>
<publisher-name>The University of Chicago Press</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1086/520600</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Diagnostics</subject>
<subj-group subj-group-type="heading">
<subject>Supplement Articles</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Diagnostic Reverse-Transcription Polymerase Chain Reaction Kit for Filoviruses Based on the Strain Collections of all European Biosafety Level 4 Laboratories</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Panning</surname>
<given-names>Marcus</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Laue</surname>
<given-names>Thomas</given-names>
</name>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ölschlager</surname>
<given-names>Stephan</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Eickmann</surname>
<given-names>Markus</given-names>
</name>
<xref ref-type="aff" rid="aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Becker</surname>
<given-names>Stephan</given-names>
</name>
<xref ref-type="aff" rid="aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Raith</surname>
<given-names>Sabine</given-names>
</name>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Courbot</surname>
<given-names>Marie-Claude Georges</given-names>
</name>
<xref ref-type="aff" rid="aff5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nilsson</surname>
<given-names>Mikael</given-names>
</name>
<xref ref-type="aff" rid="aff6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gopal</surname>
<given-names>Robin</given-names>
</name>
<xref ref-type="aff" rid="aff7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lundkvist</surname>
<given-names>Ake</given-names>
</name>
<xref ref-type="aff" rid="aff6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>di Caro</surname>
<given-names>Antonino</given-names>
</name>
<xref ref-type="aff" rid="aff9">9</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Brown</surname>
<given-names>David</given-names>
</name>
<xref ref-type="aff" rid="aff7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Meyer</surname>
<given-names>Hermann</given-names>
</name>
<xref ref-type="aff" rid="aff4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lloyd</surname>
<given-names>Graham</given-names>
</name>
<xref ref-type="aff" rid="aff8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kümmerer</surname>
<given-names>Beate M.</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Günther</surname>
<given-names>Stephan</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Drosten</surname>
<given-names>Christian</given-names>
</name>
<xref ref-type="corresp" rid="COR1"></xref>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<aff id="aff1">
<label>1</label><institution>Bernhard-Nocht Institute for Tropical Medicine</institution>, <addr-line>Hamburg</addr-line>
</aff>
<aff id="aff2">
<label>2</label><institution>Qiagen</institution>, <addr-line>Hamburg</addr-line>
</aff>
<aff id="aff3">
<label>3</label><institution>University of Marburg</institution>, <addr-line>Marburg, Germany</addr-line>
</aff>
<aff id="aff4">
<label>4</label><institution>Bundeswehr Institute of Microbiology</institution>, <addr-line>Munich, Germany</addr-line>
</aff>
<aff id="aff5">
<label>5</label><institution>Unité de Biologie des Infections Virales Emergentes, Institut Pasteur</institution>, <addr-line>Lyon, France</addr-line>
</aff>
<aff id="aff6">
<label>6</label><institution>Swedish Centre for Infectious Disease Control</institution>, <addr-line>Solna, Sweden</addr-line>
</aff>
<aff id="aff7">
<label>7</label><institution>Health Protection Agency</institution>, <addr-line>London, United Kingdom</addr-line>
</aff>
<aff id="aff8">
<label>8</label><institution>Health Protection Agency Porton Down, Salisbury</institution>, <addr-line>United Kingdom</addr-line>
</aff>
<aff id="aff9">
<label>9</label><institution>National Institute for Infectious Diseases “L. Spallanzani”</institution>, <addr-line>Rome, Italy</addr-line>
</aff>
</contrib-group>
<author-notes>
<corresp id="COR1">Reprints or correspondence: Dr. Christian Drosten, Bernhard Nocht Institute for Tropical Medicine, Clinical Virology, Bernhard-Nocht Str. 74, 20359 Hamburg, Germany (<email>drosten@bni-hamburg.de</email>).</corresp>
</author-notes>
<pub-date pub-type="ppub">
<day>15</day>
<month>11</month>
<year>2007</year>
</pub-date>
<volume>196</volume>
<issue>Supplement_2</issue>
<fpage>S199</fpage>
<lpage>S204</lpage>
<copyright-statement>© 2007 by the Infectious Diseases Society of America</copyright-statement>
<copyright-year>2007</copyright-year>
<abstract>
<p>A network of European biosafety level 4 laboratories has designed the first industry-standard molecular assay for all filoviruses species, based on the strain collections of all participants. It uses 5 optimized L gene primers and 3 probes, as well as an internal control with a separate detection probe. Detection limits (probit analysis, 95% detection chance) were as follows: <italic>Zaire ebolavirus</italic>, 487 copies/mL of plasma; <italic>Sudan ebolavirus</italic> Maleo, 586 copies/mL; <italic>Sudan ebolavirus</italic> Gulu, 1128 copies/mL; Cote <italic>d'Ivoire ebolavirus</italic>, 537 copies/mL; <italic>Reston ebolavirus</italic>, 4546 copies/mL; <italic>Lake Victoria marburgvirus</italic> Musoke, 860 copies/mL; and <italic>Lake Victoria marburgvirus</italic> Ravn, 1551 copies/mL. The assay facilitates reliable detection or exclusion screening of filovirus infections.</p>
</abstract>
</article-meta>
</front>
<body>
<p>The family <italic>Filoviridae</italic> in the order <italic>Mononegavirales</italic> contains 2 genera of pathogenic viruses, <italic>Ebolavirus</italic> (EBOV) and <italic>Marburgvirus</italic> (MARV). EBOV comprises the species <italic>Zaire ebolavirus</italic> (ZEBOV), <italic>Sudan ebolavirus</italic> (SEBOV), <italic>Cote d'Ivoire ebolavirus</italic> (CIEBOV), and <italic>Reston ebolavirus</italic> (REBOV). As agents of human disease, filoviruses are usually encountered in the context of outbreaks in Africa. Imported cases of filovirus infection are very rare. Nevertheless, potential importation of filoviruses by returning travelers is a frequent concern because of symptom similarity with other diseases—for example, malaria—and the risk of nosocomial filovirus transmission. Although, in a confirmed outbreak situation, case definitions can partially substitute for laboratory tests [<xref ref-type="bibr" rid="R1">1</xref>], in suspected cases of importation, laboratory diagnosis is always required. Severely ill patients have to be tested for a number of hemorrhagic fever viruses (e.g., EBOV, MARV, Lassa virus, yellow fever virus, and Crimean-Congo hemorrhagic fever virus) in a very short time and with such high reliability that an excluding result can be issued [<xref ref-type="bibr" rid="R2">2</xref>]. Similar scenarios arise in the screening of sick nonhuman primates, in the monitoring of workers after laboratory accidents, and in the context of suspected bioterrorism.</p>
<p>Reliable methodology can be established only if appropriate virus material is available. However, virus strains and clinical samples are limited and are subjected to biosecurity regulations. Polymerase chain reaction (PCR) design often relies on theoretical genome information only, which, for filoviruses, is incomplete in public databases. A recent external quality-assurance study has demonstrated that the overall level of diagnostic PCR proficiency for filoviruses is low [<xref ref-type="bibr" rid="R3">3</xref>]. Real-time PCR, especially ready-to-use test kits, could improve this situation, but such reagents are not available from the industry.</p>
<p>Within a network supported by the European Union, all European biosafety level 4 (BSL4) laboratories, together with a biotechnology company (Qiagen), have developed a diagnostic real-time PCR assay for filoviruses. Strains stored in the European BSL4 laboratories were collated and sequenced, an assay reacting with all filoviruses was designed, and the assay was evaluated with representative filoviruses. The test was then converted into a prototype test kit. We present here the inhouse version of the test, as well as comprehensive evaluation data for the prototype kit.</p>
<sec sec-type="materials|methods">
<title>Materials and Methods</title>
<p>Filovirus strains were grown in Vero E6 cells under BSL4 conditions. The virus titer in supernatant was determined by immunological focus assay using EBOV- or MARV-specific antibodies. Parts of the L genes of ZEBOV Eckron (BSL4 laboratory in Marburg, Germany), Gabon 1995 (Lyon, France), Gabon 2001 (Lyon, France), and Gabon 2003 (Hamburg, Germany) were amplified and sequenced using primers EboZ-13070+ (AATGTTCTAGGATATAATCCACC), EboZ-13126+ (ACTAAACGTGTACCGGAACAATT), EboZ-13720− (TGTTGCAGTCCTTCAATCCCTCC), and EboZ-13760− (ACTAAAGAAATTTGAGCACATGA). Parts of the L gene of SEBOV Gulu (Hamburg), CIEBOV (Marburg), and MARV Ravn (Stockholm) were amplified and sequenced using primers EBO-12988+ (TTCTCAACCAARATTATWAGTGA), EBO-13007+ (AGTGATTTAAGYATYTTCATAAARGA), EBO-13752−(ATTTGAGCACAGATATACWTGTCCA), EBO-13824− (ACGGTTATACAYTGATTRTCACCCAT), and EBO-13980− (TAGATGAAACCTGARTGKACRAATGT).</p>
<p>The initial assay design used the new sequences and published data of ZEBOV Zaire95 (GenBank accession no. AY354458) and Mayinga (AY142960); SEBOV Maleo (EVU-23458); REBOV Reston (AB050936) and Pennysylvania (AF-522874); and MARV Popp (MVVIRPR), Ozolin (AY-358025), and Musoke (MRVMBGL). On inspection of the alignment, relatively conserved binding sites for primers and probes were identified. At these positions, the selection of appropriate oligonucleotides was guided by melting points, folding characteristics, and cross-hybridization properties, as determined by the Primer Express package (Applied Biosystems). The primer 3′ ends avoided the third codon position. Wobble positions in primers were avoided to guarantee reliable resynthesis of primers. When necessary, virus sequence heterogeneity was compensated for by mixing of defined oligonucleotides. The stable non-Watson-Crick base pairing T:G was not strictly adjusted for.</p>
<p>Quantified in vitro transcribed RNA was generated by cloning the reverse-transcription (RT) PCR target region, together with sufficient flanking sequence, in plasmid pCR2.1. Inserts, together with a 5′-T7 promoter sequence, were amplified with M13 plasmid-specific primers and transcribed in vitro into RNA by use of the Megascript T7 kit (Ambion). After DNAse digestion and affinity purification, transcripts were quantified by photometer and used as quantification standards.</p>
<p>To monitor the sensitivity in each single reaction of the assay, an internal competitive control was constructed. It consisted of a copy of the target RNA sequence, containing a mutagenized probe binding site that could be detected by an alternative probe, which was labeled with its own specific reporter dye. The control was generated by overlap-extension PCR on the ZEBOV plasmid, as described elsewhere [<xref ref-type="bibr" rid="R4">4</xref>], using EboZ-13126+/EboZ-13720— and mutagenic primers ATCGTTCGTTGAGCGATTAGCAGTGAACATGCCACAGTTAGAGGGAGT and CTGCTAATCGCTCAACGAACGATTGATGCTTGATGCAATAAGCTTTCTT. Mutated constructs were cloned back into pCR2.1 and transcribed into RNA.</p>
<p>The in-house version of the diagnostic assay was based on the Qiagen 1-step RT-PCR kit, using a 25-µL total reaction volume including 3 µL of RNA from the Qiagen viral RNA mini kit. Reactions were supplemented with 40 ng/µL bovine serum albumin and 400 µmol/L each dNTP. The primers used were as follows: FiloA2.4, AAGCATTTCCTAGCAATATGATGGT (200 nmol/L); FiloA2.2, AAGCCTTTCCTAGCAACATGATGGT (200 nmol/L); FiloA2.3, AAGCATTCCCTAGCAACATGATGGT (200 nmol/L); Filo B, ATGTGGTGGGTTATAATAATCACTGACATG (300 nmol/L); and Filo B-Ra, GTGAGGAGGGCTATAAAAGTCACTGACATG (300 nmol/L). Probes included FAMEBOSu, FAM-CCGAAATCATCACTIGTITGGTGCCA- BlackHole Quencher 1 (BHQ1) (66.7 nmol/L); FAMEBOg, FAM-CCAAAATCATCACTIGTGTGGTGCCABHQ1 (66.7 nmol/L); FAMMBG, FAM-CCTATGCTTGCTGAATTGTGGTGCCA-BHQ1 (66.7 nmol/L); and YFPX, DyXLATCGTTCGTTGAGCGATTAGCAG-BHQ1. All probes were synthesized by Tib-Molbiol (Berlin, Germany). Amplification in a Roche Light Cycler 1.2 involved the following steps: 50°C for 30 min; 95°C for 15 min; and 45 × 95°C for 15 s, 52°C for 25 s, and 72°C for 20 s. Fluorescence was measured in each cycle at the 52°C step. The virus signal was read at the F1 wavelength, and the internal control signal was read at the F2 wavelength.</p>
</sec>
<sec sec-type="Results">
<title>Results</title>
<p>The L gene of filoviruses was selected because a pair of primers targeting this gene (Filo-A and Filo-B) has been used successfully in a number of previous studies [<xref ref-type="bibr" rid="R5">5</xref>–<xref ref-type="bibr" rid="R9">9</xref>]. Seven new sequences for the target region were generated (GenBank accession no. EF490228, SEBOV Gulu 10/200; EF490229, ZEBOV Gabon 1995; EF490230, ZEBOV Gabon 2003; EF490231, ZEBOV Gabon 2001; EF490232, MARV Ravn; EF490233, CIEBOV) and used for assay design, together with the 8 sequences available at that time. Initially, attempts were made to keep the published Filo-A/Filo-B primer positions. However, Filo-A was not very appropriate for REBOV and CIEBOV. It was shifted downstream (positive mRNA sense), and a mix of 3 primers was used at a more appropriate binding site. This was also beneficial for obtaining a short amplification fragment, as required in probe-based real-time RT-PCR. Primer Filo-B could be kept, but it was supplemented by an additional oligonucleotide that was more specific for MARV. Three detection probes were formulated separately for ZEBOV/REBOV, SEBOV/CIEBOV, and MARV, as shown in <xref ref-type="fig" rid="fig1">figure 1</xref><italic>A</italic>. With inosine-containing probes, it was possible to compensate for as many as 4 nucleotide mismatches, as maximally observed in EBOV, without losing signal intensity (<xref ref-type="fig" rid="fig1">figure 1</xref><italic>B</italic> and <xref ref-type="fig" rid="fig1">1</xref><italic>C</italic>). For MARV, such an adaptation was not necessary. There was no need to change the assay design in view of more recently published filovirus sequences [<xref ref-type="bibr" rid="R10">10</xref>]. <xref ref-type="fig" rid="fig1">Figure 1</xref><italic>A</italic> provides a summary of sequence diversity observed at all oligonucleotide binding sites, as updated in October 2006. Sequences from the 2005 outbreak of MARV infection in Uige, Angola, were not yet published when oligonucleotides were designed for this study, but compatibility with these sequences was confirmed to us before publication [<xref ref-type="bibr" rid="R11">11</xref>].</p>
<p>The mixing of detection probes for EBOV and MARV in 1 reaction led to a slight decrease in plateau fluorescence signal, as opposed to that seen with separate detection. However, it did not affect the overall assay sensitivity. As shown in <xref ref-type="fig" rid="fig1">figure 1</xref><italic>D</italic>, RNA of all tested strains was detectable at high sensitivity, ∼10 copies/assay. Primer and probe combinations were tested on genomic RNA extracted from virus preparations. Amounts of ⩽0.1 pfu of ZEBOV, SEBOV, or MARV could be detected per assay. The assay was now supplemented with a competitive internal control, for which an optimal working concentration of 50 copies/assay was determined by cross-titration against a constant low amount of target RNA (<xref ref-type="fig" rid="fig1">figure 1</xref>).</p>
<p>The limit of detection of the in-house assay was determined by probit analyses, as described elsewhere [<xref ref-type="bibr" rid="R5">5</xref>, <xref ref-type="bibr" rid="R12">12</xref>]. These experiments used quantified in vitro transcribed RNA of SEBOV Gulu and MARV Musoke. SEBOV was detected with a >95% chance if plasma contained at least 1144 RNA copies/mL (95% confidence interval [CI], 826-4088 copies/mL). The corresponding number for MARV Musoke was 1508 copies/mL (95% CI, 958-5251 copies/mL).</p>
<p>Specificity for filoviruses was confirmed using a panel of heterologous viruses. The assay did not cross-react with RNA extracted from undiluted cell culture supernatants of Lassa virus, Crimean-Congo hemorrhagic fever virus, dengue virus, Epstein-Barr virus, herpes simplex virus type 1, hepatitis C virus, HIV type 1, Japanese encephalitis virus, yellow fever virus, West Nile virus, polio virus, Ross River virus, Barmah Forest virus, Sindbis virus, and Venezuelan equine encephalitis virus.</p>
<p>The assay was transformed into a prototype “artus Filovirus LC RT-PCR Kit,” using proprietary technology, preserving oligonucleotides as described. A proprietary noncompetitive internal control RNA was included instead of the competitive internal control used in the in-house version. Sensitivity was evaluated on plaque-quantified virus stock material, as shown in <xref ref-type="fig" rid="fig2">figure 2</xref>, as well as on sample panels froma recent proficiency testing study [<xref ref-type="bibr" rid="R3">3</xref>]. All filovirus samples from this study were correctly detected, and all RNA quantification results showed <1 log<sub>10</sub> deviation from predetermined data [<xref ref-type="bibr" rid="R3">3</xref>]. Clinical specimens were available from 2 patients: 1 serum sample from an outbreak of SEBOV infection in Uganda and 1 buccal swab from an outbreak of ZEBOV infection in Gabon. Testing of both materials by RT-PCR has been described elsewhere [<xref ref-type="bibr" rid="R1">1</xref>, <xref ref-type="bibr" rid="R5">5</xref>]. Both were readily detected with the assay.</p>
<p>Intra- and interassay variability were also determined.Twenty parallel determinations in 1 run on a sample containing 1000 copies/reaction yielded an intra-assay coefficient of variation of 0.66% (based on an average crossing point value of 32.95). When the same sample was tested in 11 independent runs, an interassay coefficient of variation of 1% was seen at an average crossing point value of 32.65. The precise limits of detection were determined for a collection of virus strains representing the spectrum of genetic diversity at the oligonucleotide binding sites. Results of probit analyses are summarized in <xref ref-type="fig" rid="fig2">figure 2</xref>.</p>
</sec>
<sec sec-type="conclusions">
<title>Conclusions</title>
<p>Recent studies of rare pathogens, such as severe acute respiratory syndrome (SARS) coronavirus, orthopox viruses, or West Nile virus, have shown that the availability of ready-made test kits positively influences laboratory performance [<xref ref-type="bibr" rid="R13">13</xref>–<xref ref-type="bibr" rid="R15">15</xref>]. The feasibility of developing such kits through close collaboration with industry has been demonstrated in connection with the SARS outbreak in 2003, when a test kit was made available during the epidemic. The main purpose of the present study was to design a similar kit for filoviruses. Most of the preliminary work was done by academic and governmental institutions, lowering the financial entry threshold for a company that collaborated as a network partner. Kits could be produced in accordance with high quality standards, with features comparable to those of commercial diagnostic PCR systems (e.g., HIV- 1, hepatitis C virus, and hepatitis B virus). This is the first probe-based assay compatible with all known filovirus species. An internal control monitors the sensitivity in every single reaction. Analytical properties have been evaluated in accordance with industry-approved standards, such as probit analysis with a broad range of filovirus strains, intra- and inter-assay variability analysis, and specificity testing with an exhaustive panel of viruses causing related clinical manifestations. These data not only will ensure wide acceptance of the assay as a standard test in Europe but could also serve as an entry point into production as an in vitro diagnostic procedure.</p>
<p>Irrespective of whether the assay is used in its in-house version or as a reagent kit, it can never be guaranteed that a PCR assay will detect unknown filovirus strains that may emerge in the future. The diagnostics of filovirus infection should always be based on the whole range of diagnostic tests, including PCR, antigen testing, antibody detection, and virus culture. Moreover, new technical developments and novel virus strains impose continued work on molecular assays. The present study has shown that such work is possible only through collaboration and exchange of virus material. In view of expanding restrictions in the context of biosecurity, care has to be taken that such indispensable collaboration will still be possible in the future.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>We are grateful to Stuart T. Nichol for communicating unpublished sequence data from the 2005 outbreak of Marburg virus infection in Uige, Angola. We thank Carola Busch, Beate Becker-Ziaja, and Britta Liedigk for excellent technical assistance.</p>
<p><bold><italic>Supplement sponsorship.</italic></bold> This article was published as part of a supplement entitled “Filoviruses: Recent Advances and Future Challenges,” sponsored by the Public Health Agency of Canada, the National Institutes of Health, the Canadian Institutes of Health Research, Cangene, CUH2A, Smith Carter, Hemisphere Engineering, Crucell, and the International Centre for Infectious Diseases.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="R1">
<label>1.</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Formenty</surname><given-names>P</given-names></name>
<name><surname>Leroy</surname><given-names>EM</given-names></name>
<name><surname>Epelboin</surname><given-names>A</given-names></name>
<etal></etal>
</person-group>
<article-title>Detection of Ebola virus in oral fluid specimens during outbreaks of Ebola virus hemorrhagic fever in the Republic of Congo</article-title>
<source>Clin Infect Dis</source>
<year>2006</year>
<volume>42</volume>
<fpage>1521</fpage>
<lpage>6</lpage>
</nlm-citation>
</ref>
<ref id="R2">
<label>2.</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Drosten</surname><given-names>C</given-names></name>
<name><surname>Kummerer</surname><given-names>BM</given-names></name>
<name><surname>Schmitz</surname><given-names>H</given-names></name>
<name><surname>Gunther</surname><given-names>S</given-names></name>
</person-group>
<article-title>Molecular diagnostics of viral hemorrhagic fevers</article-title>
<source>Antiviral Res</source>
<year>2003</year>
<volume>57</volume>
<fpage>61</fpage>
<lpage>87</lpage>
</nlm-citation>
</ref>
<ref id="R3">
<label>3.</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Niedrig</surname><given-names>M</given-names></name>
<name><surname>Schmitz</surname><given-names>H</given-names></name>
<name><surname>Becker</surname><given-names>S</given-names></name>
<etal></etal>
</person-group>
<article-title>First international quality assurance study on the rapid detection of viral agents of bioterrorism</article-title>
<source>J Clin Microbiol</source>
<year>2004</year>
<volume>42</volume>
<fpage>1753</fpage>
<lpage>5</lpage>
</nlm-citation>
</ref>
<ref id="R4">
<label>4.</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Drosten</surname><given-names>C</given-names></name>
<name><surname>Weber</surname><given-names>M</given-names></name>
<name><surname>Seifried</surname><given-names>E</given-names></name>
<name><surname>Roth</surname><given-names>WK</given-names></name>
</person-group>
<article-title>Evaluation of a new PCR assay with competitive internal control sequence for blood donor screening</article-title>
<source>Transfusion</source>
<year>2000</year>
<volume>40</volume>
<fpage>718</fpage>
<lpage>24</lpage>
</nlm-citation>
</ref>
<ref id="R5">
<label>5.</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Drosten</surname><given-names>C</given-names></name>
<name><surname>Gottig</surname><given-names>S</given-names></name>
<name><surname>Schilling</surname><given-names>S</given-names></name>
<etal></etal>
</person-group>
<article-title>Rapid detection and quantification of RNA of Ebola and Marburg viruses, Lassa virus, Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus, dengue virus, and yellow fever virus by real-time reverse transcription-PCR</article-title>
<source>J Clin Microbiol</source>
<year>2002</year>
<volume>40</volume>
<fpage>2323</fpage>
<lpage>30</lpage>
</nlm-citation>
</ref>
<ref id="R6">
<label>6.</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sanchez</surname><given-names>A</given-names></name>
<name><surname>Ksiazek</surname><given-names>TG</given-names></name>
<name><surname>Rollin</surname><given-names>PE</given-names></name>
<etal></etal>
</person-group>
<article-title>Detection and molecular characterization of Ebola viruses causing disase in human and nonhuman primates</article-title>
<source>J Infect Dis</source>
<year>1999</year>
<volume>179</volume>
<issue>(Suppl 1)</issue>
<fpage>S164</fpage>
<lpage>9</lpage>
</nlm-citation>
</ref>
<ref id="R7">
<label>7.</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Towner</surname><given-names>JS</given-names></name>
<name><surname>Rollin</surname><given-names>PE</given-names></name>
<name><surname>Bausch</surname><given-names>DG</given-names></name>
<etal></etal>
</person-group>
<article-title>Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome</article-title>
<source>J Virol</source>
<year>2004</year>
<volume>78</volume>
<fpage>4330</fpage>
<lpage>41</lpage>
</nlm-citation>
</ref>
<ref id="R8">
<label>8.</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Leroy</surname><given-names>EM</given-names></name>
<name><surname>Baize</surname><given-names>S</given-names></name>
<name><surname>Lu</surname><given-names>CY</given-names></name>
<etal></etal>
</person-group>
<article-title>Diagnosis of Ebola haemorrhagic fever by RT-PCR in an epidemic setting</article-title>
<source>J Med Virol</source>
<year>2000</year>
<volume>60</volume>
<fpage>463</fpage>
<lpage>7</lpage>
</nlm-citation>
</ref>
<ref id="R9">
<label>9.</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Leroy</surname><given-names>EM</given-names></name>
<name><surname>Baize</surname><given-names>S</given-names></name>
<name><surname>Volchkov</surname><given-names>VE</given-names></name>
<etal></etal>
</person-group>
<article-title>Human asymptomatic Ebola infection and strong inflammatory response</article-title>
<source>Lancet</source>
<year>2000</year>
<volume>355</volume>
<fpage>2210</fpage>
<lpage>5</lpage>
</nlm-citation>
</ref>
<ref id="R10">
<label>10.</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bausch</surname><given-names>DG</given-names></name>
<name><surname>Nichol</surname><given-names>ST</given-names></name>
<name><surname>Muyembe-Tamfum</surname><given-names>JJ</given-names></name>
<etal></etal>
</person-group>
<article-title>Marburg hemorrhagic fever associated with multiple genetic lineages of virus</article-title>
<source>N Engl J Med</source>
<year>2006</year>
<volume>355</volume>
<fpage>909</fpage>
<lpage>19</lpage>
</nlm-citation>
</ref>
<ref id="R11">
<label>11.</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Towner</surname><given-names>JS</given-names></name>
<name><surname>Khristova</surname><given-names>ML</given-names></name>
<name><surname>Sealy</surname><given-names>TK</given-names></name>
<etal></etal>
</person-group>
<article-title>Marburgvirus genomics and association with a large hemorrhagic fever outbreak in Angola</article-title>
<source>J Virol</source>
<year>2006</year>
<volume>80</volume>
<fpage>6497</fpage>
<lpage>516</lpage>
</nlm-citation>
</ref>
<ref id="R12">
<label>12.</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Drosten</surname><given-names>C</given-names></name>
<name><surname>Chiu</surname><given-names>LL</given-names></name>
<name><surname>Panning</surname><given-names>M</given-names></name>
<etal></etal>
</person-group>
<article-title>Evaluation of advanced reverse transcription-PCR assays and an alternative PCR target region for detection of severe acute respiratory syndrome-associated coronavirus</article-title>
<source>J Clin Microbiol</source>
<year>2004</year>
<volume>42</volume>
<fpage>2043</fpage>
<lpage>7</lpage>
</nlm-citation>
</ref>
<ref id="R13">
<label>13.</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Drosten</surname><given-names>C</given-names></name>
<name><surname>Doerr</surname><given-names>HW</given-names></name>
<name><surname>Lim</surname><given-names>W</given-names></name>
<name><surname>Stohr</surname><given-names>K</given-names></name>
<name><surname>Niedrig</surname><given-names>M</given-names></name>
</person-group>
<article-title>SARS molecular detection external quality assurance</article-title>
<source>Emerg Infect Dis</source>
<year>2004</year>
<volume>10</volume>
<fpage>2200</fpage>
<lpage>3</lpage>
</nlm-citation>
</ref>
<ref id="R14">
<label>14.</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Niedrig</surname><given-names>M</given-names></name>
<name><surname>Meyer</surname><given-names>H</given-names></name>
<name><surname>Panning</surname><given-names>M</given-names></name>
<name><surname>Drosten</surname><given-names>C</given-names></name>
</person-group>
<article-title>Follow-up on diagnostic proficiency of laboratories equipped to perform orthopoxvirus detection and quantification by PCR: the second international external quality assurance study</article-title>
<source>J Clin Microbiol</source>
<year>2006</year>
<volume>44</volume>
<fpage>1283</fpage>
<lpage>7</lpage>
</nlm-citation>
</ref>
<ref id="R15">
<label>15.</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Niedrig</surname><given-names>M</given-names></name>
<name><surname>Linke</surname><given-names>S</given-names></name>
<name><surname>Zeller</surname><given-names>H</given-names></name>
<name><surname>Drosten</surname><given-names>C</given-names></name>
</person-group>
<article-title>First international proficiency study on West Nile virus molecular detection</article-title>
<source>Clin Chem</source>
<year>2006</year>
<volume>52</volume>
<fpage>1851</fpage>
<lpage>4</lpage>
</nlm-citation>
</ref>
</ref-list>
<sec sec-type="display-objects">
<title>Figures and Tables</title>
<fig position="float" id="fig1">
<label>Figure 1</label>
<caption>
<p>Design of the in-house assay serving as a basis for the test kit. <italic>A</italic>, Binding sites of oligonucleotides. Letters in the left column represent the species (Z, <italic>Zaire ebolavirus</italic> [ZEBOV]; IC, <italic>Cote d'Ivoire ebolavirus</italic> [CIEBOV]; RE, <italic>Reston ebolavirus</italic> [REBOV]; S, <italic>Sudan ebolavirus</italic> [SEBOV]; and M, <italic>Lake Victoria marburgvirus</italic> [MARV]), followed by a representative strain designation (GenBank accession nos. or sequences from in-house strain collections). Note that only representative sequences are shown. All sequences occurring more than once at each of the oligonucleotide binding sites have been deleted from the alignment. The alignment was updated in October 2006 with latest GenBank entries. The complete alignment can be retrieved from <ext-link ext-link-type="uri" xlink:href="http://www.bni-hamburg.de/ebovalign">http://www.bni-hamburg.de/ebovalign</ext-link>. <italic>B</italic>, A probe matching ZEBOV <italic>(top panel)</italic>, modified to adapt a single nucleotide mismatch as present in REBOV (probe EBOg, <italic>lower panel</italic>). No loss of signal occurred for ZEBOV <italic>(bottom panel)</italic>, and the signal for REBOV improved (not shown; REBOV was not yet available at the time these experiments were performed). <italic>C, top panel</italic>, A probe containing 2 inosin residues at positions of variability but otherwise matching SEBOV (probe EBOSu), yielding a good detection signal (similar to the signal from a corresponding RNA concentration of ZEBOV; compare with panel B). <italic>C, middle panel</italic>, A probe of similar design, adapted to CIEBOV, yielding good signal for CIEBOV. However, because CIEBOV was also detectable with good efficiency with the EBOSu probe <italic>(C, bottom panel)</italic>, EBOSu was used for both SEBOV and CIEBOV. <italic>D</italic>, Detection signals with oligonucleotides, as shown in panel A, in reactions containing low concentrations of virus RNA (flat lines denote controls; the figure shows signals with all probes and primers mixed in 1 reaction). <italic>E</italic>, Determination of working concentration for competitive internal control. A constant small amount of target gene RNA (<italic>solid line</italic>; 50 copies of ZEBOV transcript per assay) was amplified in the presence of increasing concentrations, as plotted on the X-axis, of the internal control <italic>(dotted line)</italic>. Observed crossing point values were plotted on the <italic>Y</italic>-axis for both target genes (note that the virus and internal control carried different reporter dyes). Increasing values on the <italic>Y</italic>-axis indicate decreasing amplification efficiencies. From 40 copies of internal control onward, stable amplification was possible. From 400 copies/reaction (cps/rxn) onward, amplification of ZEBOV RNA lost efficiency, as is represented by the increasing crossing point value.</p>
</caption>
<graphic mimetype="image" xlink:href="196-Supplement_2-S199-fig001.tif"></graphic>
</fig>
<fig position="float" id="fig2">
<label>Figure 2</label>
<caption>
<p>Performance of the ready-made filovirus test kit. <italic>A</italic>, Testing of plaque-quantified virus stock solutions. Virus was diluted in virus-negative human serum to the listed concentrations and tested in 4 replicate assays each. +, positive result; − negative result; RT-PCR, reverse-transcription polymerase chain reaction. <italic>B</italic>, Probit analysis on replicated tests (typically 6 tests per concentration) of virus-negative human serum inoculated on the level of the lysis buffer with given concentrations (<italic>X</italic>-axis) of filovirus RNA in vitro transcripts. The observed rates of positive results per total no. of tests performed are plotted on the <italic>Y</italic>-axis. Nos. in each panel are the concentrations beyond which the statistical chance of detection exceeds 95%, according to the probit model (dose-response relationship). Nos. in parenthesis are 95% confidence intervals for these numbers. cps, copies.</p>
</caption>
<graphic mimetype="image" xlink:href="196-Supplement_2-S199-fig002.tif"></graphic>
</fig>
</sec>
<fn-group>
<fn fn-type="other">
<p>Potential conflicts of interest: none reported.</p>
</fn>
<fn fn-type="financial-disclosure">
<p>Financial support: European Commission (contracts SSPE-CT-2003-502567 and SSPE-CT-2005-022639); Bundeswehr (contract E/B41G/1G309/1A403); Bundesamt für Bevölkerungsschutz und Katastrophenhilfe (contract BBK-F-440-00-1). Supplement sponsorship is detailed in the Acknowledgments.</p>
</fn>
</fn-group>
</back>
</article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo><title>Diagnostic Reverse-Transcription Polymerase Chain Reaction Kit for Filoviruses Based on the Strain Collections of all European Biosafety Level 4 Laboratories</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>Diagnostic Reverse-Transcription Polymerase Chain Reaction Kit for Filoviruses Based on the Strain Collections of all European Biosafety Level 4 Laboratories</title></titleInfo><name type="personal"><namePart type="given">Marcus</namePart><namePart type="family">Panning</namePart><affiliation>Bernhard-Nocht Institute for Tropical Medicine, Hamburg</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Thomas</namePart><namePart type="family">Laue</namePart><affiliation>Qiagen, Hamburg</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Stephan</namePart><namePart type="family">Ölschlager</namePart><affiliation>Bernhard-Nocht Institute for Tropical Medicine, Hamburg</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Markus</namePart><namePart type="family">Eickmann</namePart><affiliation>University of Marburg, Marburg, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Stephan</namePart><namePart type="family">Becker</namePart><affiliation>University of Marburg, Marburg, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Sabine</namePart><namePart type="family">Raith</namePart><affiliation>Qiagen, Hamburg</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Marie-Claude Georges</namePart><namePart type="family">Courbot</namePart><affiliation>Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Mikael</namePart><namePart type="family">Nilsson</namePart><affiliation>Swedish Centre for Infectious Disease Control, Solna, Sweden</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Robin</namePart><namePart type="family">Gopal</namePart><affiliation>Health Protection Agency, London, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Ake</namePart><namePart type="family">Lundkvist</namePart><affiliation>Swedish Centre for Infectious Disease Control, Solna, Sweden</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Antonino</namePart><namePart type="family">di Caro</namePart><affiliation>National Institute for Infectious Diseases “L. Spallanzani”, Rome, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">David</namePart><namePart type="family">Brown</namePart><affiliation>Health Protection Agency, London, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Hermann</namePart><namePart type="family">Meyer</namePart><affiliation>Bundeswehr Institute of Microbiology, Munich, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Graham</namePart><namePart type="family">Lloyd</namePart><affiliation>Health Protection Agency Porton Down, Salisbury, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Beate M.</namePart><namePart type="family">Kümmerer</namePart><affiliation>Bernhard-Nocht Institute for Tropical Medicine, Hamburg</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Stephan</namePart><namePart type="family">Günther</namePart><affiliation>Bernhard-Nocht Institute for Tropical Medicine, Hamburg</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal" displayLabel="corresp"><namePart type="given">Christian</namePart><namePart type="family">Drosten</namePart><affiliation>Bernhard-Nocht Institute for Tropical Medicine, Hamburg</affiliation><affiliation>E-mail: drosten@bni-hamburg.de</affiliation><affiliation>Reprints or correspondence: Dr. Christian Drosten, Bernhard Nocht Institute for Tropical Medicine, Clinical Virology, Bernhard-Nocht Str. 74, 20359 Hamburg, Germany (drosten@bni-hamburg.de).</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="research-article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</genre><originInfo><publisher>The University of Chicago Press</publisher><dateIssued encoding="w3cdtf">2007-11-15</dateIssued><copyrightDate encoding="w3cdtf">2007</copyrightDate></originInfo><abstract>A network of European biosafety level 4 laboratories has designed the first industry-standard molecular assay for all filoviruses species, based on the strain collections of all participants. It uses 5 optimized L gene primers and 3 probes, as well as an internal control with a separate detection probe. Detection limits (probit analysis, 95% detection chance) were as follows: Zaire ebolavirus, 487 copies/mL of plasma; Sudan ebolavirus Maleo, 586 copies/mL; Sudan ebolavirus Gulu, 1128 copies/mL; Cote d'Ivoire ebolavirus, 537 copies/mL; Reston ebolavirus, 4546 copies/mL; Lake Victoria marburgvirus Musoke, 860 copies/mL; and Lake Victoria marburgvirus Ravn, 1551 copies/mL. The assay facilitates reliable detection or exclusion screening of filovirus infections.</abstract><relatedItem type="host"><titleInfo><title>The Journal of Infectious Diseases</title></titleInfo><titleInfo type="abbreviated"><title>The Journal of Infectious Diseases</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><identifier type="ISSN">0022-1899</identifier><identifier type="eISSN">1537-6613</identifier><identifier type="PublisherID">jid</identifier><identifier type="PublisherID-hwp">jinfdis</identifier><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>196</number></detail><detail type="issue"><caption>no.</caption><number>Supplement-2</number></detail><extent unit="pages"><start>S199</start><end>S204</end></extent></part></relatedItem><relatedItem type="references" displayLabel="R1"><titleInfo><title>Detection of Ebola virus in oral fluid specimens during outbreaks of Ebola virus hemorrhagic fever in the Republic of Congo</title></titleInfo><name type="personal"><namePart type="given">P</namePart><namePart type="family">Formenty</namePart></name><name type="personal"><namePart type="given">EM</namePart><namePart type="family">Leroy</namePart></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Epelboin</namePart></name><genre>journal</genre><note>FormentyP LeroyEM EpelboinA Detection of Ebola virus in oral fluid specimens during outbreaks of Ebola virus hemorrhagic fever in the Republic of Congo Clin Infect Dis 2006 42 1521 6</note><relatedItem type="host"><titleInfo><title>Clin Infect Dis</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>42</number></detail><extent unit="pages"><start>1521</start><end>6</end><list>1521-6</list></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="R2"><titleInfo><title>Molecular diagnostics of viral hemorrhagic fevers</title></titleInfo><name type="personal"><namePart type="given">C</namePart><namePart type="family">Drosten</namePart></name><name type="personal"><namePart type="given">BM</namePart><namePart type="family">Kummerer</namePart></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Schmitz</namePart></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Gunther</namePart></name><genre>journal</genre><note>DrostenC KummererBM SchmitzH GuntherS Molecular diagnostics of viral hemorrhagic fevers Antiviral Res 2003 57 61 87</note><relatedItem type="host"><titleInfo><title>Antiviral Res</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>57</number></detail><extent unit="pages"><start>61</start><end>87</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="R3"><titleInfo><title>First international quality assurance study on the rapid detection of viral agents of bioterrorism</title></titleInfo><name type="personal"><namePart type="given">M</namePart><namePart type="family">Niedrig</namePart></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Schmitz</namePart></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Becker</namePart></name><genre>journal</genre><note>NiedrigM SchmitzH BeckerS First international quality assurance study on the rapid detection of viral agents of bioterrorism J Clin Microbiol 2004 42 1753 5</note><relatedItem type="host"><titleInfo><title>J Clin Microbiol</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>42</number></detail><extent unit="pages"><start>1753</start><end>5</end><list>1753-5</list></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="R4"><titleInfo><title>Evaluation of a new PCR assay with competitive internal control sequence for blood donor screening</title></titleInfo><name type="personal"><namePart type="given">C</namePart><namePart type="family">Drosten</namePart></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Weber</namePart></name><name type="personal"><namePart type="given">E</namePart><namePart type="family">Seifried</namePart></name><name type="personal"><namePart type="given">WK</namePart><namePart type="family">Roth</namePart></name><genre>journal</genre><note>DrostenC WeberM SeifriedE RothWK Evaluation of a new PCR assay with competitive internal control sequence for blood donor screening Transfusion 2000 40 718 24</note><relatedItem type="host"><titleInfo><title>Transfusion</title></titleInfo><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>40</number></detail><extent unit="pages"><start>718</start><end>24</end><list>718-24</list></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="R5"><titleInfo><title>Rapid detection and quantification of RNA of Ebola and Marburg viruses, Lassa virus, Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus, dengue virus, and yellow fever virus by real-time reverse transcription-PCR</title></titleInfo><name type="personal"><namePart type="given">C</namePart><namePart type="family">Drosten</namePart></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Gottig</namePart></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Schilling</namePart></name><genre>journal</genre><note>DrostenC GottigS SchillingS Rapid detection and quantification of RNA of Ebola and Marburg viruses, Lassa virus, Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus, dengue virus, and yellow fever virus by real-time reverse transcription-PCR J Clin Microbiol 2002 40 2323 30</note><relatedItem type="host"><titleInfo><title>J Clin Microbiol</title></titleInfo><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>40</number></detail><extent unit="pages"><start>2323</start><end>30</end><list>2323-30</list></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="R6"><titleInfo><title>Detection and molecular characterization of Ebola viruses causing disase in human and nonhuman primates</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">Sanchez</namePart></name><name type="personal"><namePart type="given">TG</namePart><namePart type="family">Ksiazek</namePart></name><name type="personal"><namePart type="given">PE</namePart><namePart type="family">Rollin</namePart></name><genre>journal</genre><note>SanchezA KsiazekTG RollinPE Detection and molecular characterization of Ebola viruses causing disase in human and nonhuman primates J Infect Dis 1999 179 (Suppl 1) S164 9</note><relatedItem type="host"><titleInfo><title>J Infect Dis</title></titleInfo><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>179</number></detail><detail type="issue"><caption>no.</caption><number>(Suppl 1)</number></detail><extent unit="pages"><start>S164</start><end>9</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="R7"><titleInfo><title>Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome</title></titleInfo><name type="personal"><namePart type="given">JS</namePart><namePart type="family">Towner</namePart></name><name type="personal"><namePart type="given">PE</namePart><namePart type="family">Rollin</namePart></name><name type="personal"><namePart type="given">DG</namePart><namePart type="family">Bausch</namePart></name><genre>journal</genre><note>TownerJS RollinPE BauschDG Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome J Virol 2004 78 4330 41</note><relatedItem type="host"><titleInfo><title>J Virol</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>78</number></detail><extent unit="pages"><start>4330</start><end>41</end><list>4330-41</list></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="R8"><titleInfo><title>Diagnosis of Ebola haemorrhagic fever by RT-PCR in an epidemic setting</title></titleInfo><name type="personal"><namePart type="given">EM</namePart><namePart type="family">Leroy</namePart></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Baize</namePart></name><name type="personal"><namePart type="given">CY</namePart><namePart type="family">Lu</namePart></name><genre>journal</genre><note>LeroyEM BaizeS LuCY Diagnosis of Ebola haemorrhagic fever by RT-PCR in an epidemic setting J Med Virol 2000 60 463 7</note><relatedItem type="host"><titleInfo><title>J Med Virol</title></titleInfo><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>60</number></detail><extent unit="pages"><start>463</start><end>7</end><list>463-7</list></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="R9"><titleInfo><title>Human asymptomatic Ebola infection and strong inflammatory response</title></titleInfo><name type="personal"><namePart type="given">EM</namePart><namePart type="family">Leroy</namePart></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Baize</namePart></name><name type="personal"><namePart type="given">VE</namePart><namePart type="family">Volchkov</namePart></name><genre>journal</genre><note>LeroyEM BaizeS VolchkovVE Human asymptomatic Ebola infection and strong inflammatory response Lancet 2000 355 2210 5</note><relatedItem type="host"><titleInfo><title>Lancet</title></titleInfo><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>355</number></detail><extent unit="pages"><start>2210</start><end>5</end><list>2210-5</list></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="R10"><titleInfo><title>Marburg hemorrhagic fever associated with multiple genetic lineages of virus</title></titleInfo><name type="personal"><namePart type="given">DG</namePart><namePart type="family">Bausch</namePart></name><name type="personal"><namePart type="given">ST</namePart><namePart type="family">Nichol</namePart></name><name type="personal"><namePart type="given">JJ</namePart><namePart type="family">Muyembe-Tamfum</namePart></name><genre>journal</genre><note>BauschDG NicholST Muyembe-TamfumJJ Marburg hemorrhagic fever associated with multiple genetic lineages of virus N Engl J Med 2006 355 909 19</note><relatedItem type="host"><titleInfo><title>N Engl J Med</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>355</number></detail><extent unit="pages"><start>909</start><end>19</end><list>909-19</list></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="R11"><titleInfo><title>Marburgvirus genomics and association with a large hemorrhagic fever outbreak in Angola</title></titleInfo><name type="personal"><namePart type="given">JS</namePart><namePart type="family">Towner</namePart></name><name type="personal"><namePart type="given">ML</namePart><namePart type="family">Khristova</namePart></name><name type="personal"><namePart type="given">TK</namePart><namePart type="family">Sealy</namePart></name><genre>journal</genre><note>TownerJS KhristovaML SealyTK Marburgvirus genomics and association with a large hemorrhagic fever outbreak in Angola J Virol 2006 80 6497 516</note><relatedItem type="host"><titleInfo><title>J Virol</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>80</number></detail><extent unit="pages"><start>6497</start><end>516</end><list>6497-516</list></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="R12"><titleInfo><title>Evaluation of advanced reverse transcription-PCR assays and an alternative PCR target region for detection of severe acute respiratory syndrome-associated coronavirus</title></titleInfo><name type="personal"><namePart type="given">C</namePart><namePart type="family">Drosten</namePart></name><name type="personal"><namePart type="given">LL</namePart><namePart type="family">Chiu</namePart></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Panning</namePart></name><genre>journal</genre><note>DrostenC ChiuLL PanningM Evaluation of advanced reverse transcription-PCR assays and an alternative PCR target region for detection of severe acute respiratory syndrome-associated coronavirus J Clin Microbiol 2004 42 2043 7</note><relatedItem type="host"><titleInfo><title>J Clin Microbiol</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>42</number></detail><extent unit="pages"><start>2043</start><end>7</end><list>2043-7</list></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="R13"><titleInfo><title>SARS molecular detection external quality assurance</title></titleInfo><name type="personal"><namePart type="given">C</namePart><namePart type="family">Drosten</namePart></name><name type="personal"><namePart type="given">HW</namePart><namePart type="family">Doerr</namePart></name><name type="personal"><namePart type="given">W</namePart><namePart type="family">Lim</namePart></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Stohr</namePart></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Niedrig</namePart></name><genre>journal</genre><note>DrostenC DoerrHW LimW StohrK NiedrigM SARS molecular detection external quality assurance Emerg Infect Dis 2004 10 2200 3</note><relatedItem type="host"><titleInfo><title>Emerg Infect Dis</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>2200</start><end>3</end><list>2200-3</list></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="R14"><titleInfo><title>Follow-up on diagnostic proficiency of laboratories equipped to perform orthopoxvirus detection and quantification by PCR: the second international external quality assurance study</title></titleInfo><name type="personal"><namePart type="given">M</namePart><namePart type="family">Niedrig</namePart></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Meyer</namePart></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Panning</namePart></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Drosten</namePart></name><genre>journal</genre><note>NiedrigM MeyerH PanningM DrostenC Follow-up on diagnostic proficiency of laboratories equipped to perform orthopoxvirus detection and quantification by PCR: the second international external quality assurance study J Clin Microbiol 2006 44 1283 7</note><relatedItem type="host"><titleInfo><title>J Clin Microbiol</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>1283</start><end>7</end><list>1283-7</list></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="R15"><titleInfo><title>First international proficiency study on West Nile virus molecular detection</title></titleInfo><name type="personal"><namePart type="given">M</namePart><namePart type="family">Niedrig</namePart></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Linke</namePart></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Zeller</namePart></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Drosten</namePart></name><genre>journal</genre><note>NiedrigM LinkeS ZellerH DrostenC First international proficiency study on West Nile virus molecular detection Clin Chem 2006 52 1851 4</note><relatedItem type="host"><titleInfo><title>Clin Chem</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>52</number></detail><extent unit="pages"><start>1851</start><end>4</end><list>1851-4</list></extent></part></relatedItem></relatedItem><identifier type="istex">132FFE9AD7A1A2EEDB40F77F78284659D4FF368A</identifier><identifier type="ark">ark:/67375/HXZ-GF4DFKKG-B</identifier><identifier type="DOI">10.1086/520600</identifier><accessCondition type="use and reproduction" contentType="copyright">© 2007 by the Infectious Diseases Society of America</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-GTWS0RDP-M">oup</recordContentSource><recordOrigin>Converted from (version 1.2.10) to MODS version 3.6.</recordOrigin><recordCreationDate encoding="w3cdtf">2020-04-16</recordCreationDate></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/HXZ-GF4DFKKG-B/record.json</uri></json:item></metadata><covers><json:item><extension>tiff</extension><original>true</original><mimetype>image/tiff</mimetype><uri>https://api.istex.fr/document/132FFE9AD7A1A2EEDB40F77F78284659D4FF368A/covers/tiff</uri></json:item></covers><annexes><json:item><extension>gif</extension><original>true</original><mimetype>image/gif</mimetype><uri>https://api.istex.fr/ark:/67375/HXZ-GF4DFKKG-B/annexes.gif</uri></json:item><json:item><extension>jpeg</extension><original>true</original><mimetype>image/jpeg</mimetype><uri>https://api.istex.fr/ark:/67375/HXZ-GF4DFKKG-B/annexes.jpeg</uri></json:item><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/HXZ-GF4DFKKG-B/annexes.pdf</uri></json:item></annexes><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C10 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000C10 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:132FFE9AD7A1A2EEDB40F77F78284659D4FF368A
|texte= Diagnostic Reverse-Transcription Polymerase Chain Reaction Kit for Filoviruses Based on the Strain Collections of all European Biosafety Level 4 Laboratories
}}
| This area was generated with Dilib version V0.6.33. |  |